MIDATECH PHARMA
Media
Sep 28, 2018
Shareholder Circular and Notice of General Meeting to be held on 15 October 2018

Shareholder Circular and Notice of General Meeting to be held on 15 October 2018.

Download read more >

Sep 28, 2018
Interim results from MTD201 exploratory study

Midatech Announces Interim Results from Proof of Concept Exploratory Study for its MTD201 Q-Octreotide Programme and... read more >

Jun 8, 2018
Midatech Pharma US enrols first patient in Gelclair® trial in stem cell transplant

Patients now being enrolled at the Dana-Farber/Brigham and Women’s Cancer Center and Massachusetts General Hospital

read more >
Jun 1, 2018
2017 Annual Report and AGM Notification

Midatech (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in... read more >

Jun 1, 2018
Board Change

Midatech (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in... read more >

May 25, 2018
Midatech commences US clinical study of its investigational treatment for fatal childhood brain cancer

Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising... read more >

May 21, 2018
Midatech commences dosing in equivalence study

Midatech commences equivalence study in exploratory phase of Q-Octreotide (MTD201) for carcinoid... read more >

Mar 15, 2018
Midatech announces changes in Senior Management Team

Midatech (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising... read more >

Jan 9, 2018
Midatech receives confirmation that its Q-Octreotide (MTD201) first in-human EU study is approved

Midatech (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising... read more >

Jan 2, 2018
Midatech enters into a Loan Agreement with MidCap Financial

Midatech (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising... read more >

Dec 20, 2017
Midatech Pharma US initiates Gelclair® Phase IV trial to study oral mucositis in stem cell transplant patients

Trial to be conducted at the Dana-Farber / Brigham and Women’s Cancer Center to determine ability... read more >

Sep 6, 2017
Midatech to present at 19th Annual Rodman & Renshaw Global Investment Conference

Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and... read more >

Sep 4, 2017
Midatech submits MTD201 CTA filing for first in human study in carcinoid cancer and acromegaly

Midatech on track to start clinical development with MTD201 in Q4 2017

Midatech Pharma (AIM: MTPH,... read more >

Jul 26, 2017
Completion of pre-clinical liver cancer programme

Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and... read more >

Jul 18, 2017
Trading Update and Notice of Results

Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and... read more >

Jun 13, 2017
R&D manufacturing site visit for investors and analysts

Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products... read more >

Jun 9, 2017
Midatech signs global license agreement to investigate panobinostat for treatment of brain cancers

Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products... read more >

May 22, 2017
Midatech announces progress update on brain cancer therapies

Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products... read more >

Apr 11, 2017
Notice of Annual General Meeting 2017
Apr 4, 2017
Audited financial results for the year ended 31 December 2016

Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products... read more >

Mar 10, 2017
Midatech Announces Successful Initial Scale-Up of Its Sustained Release Manufacturing Facility

~ Q-Octreotide will become Midatech’s first Sustained Release product candidate manufactured in house at its state-of-the-art... read more >

Jan 20, 2017
Trading Update

Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and... read more >

 

Media
Sep 28, 2018
Shareholder Circular and Notice of General Meeting to be held on 15 October 2018

Shareholder Circular and Notice of General Meeting to be held on 15 October 2018.

Download read more >

Sep 28, 2018
Interim results from MTD201 exploratory study

Midatech Announces Interim Results from Proof of Concept Exploratory Study for its MTD201 Q-Octreotide Programme and... read more >

Jun 8, 2018
Midatech Pharma US enrols first patient in Gelclair® trial in stem cell transplant

Patients now being enrolled at the Dana-Farber/Brigham and Women’s Cancer Center and Massachusetts General Hospital

read more >
Jun 1, 2018
2017 Annual Report and AGM Notification

Midatech (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in... read more >

Jun 1, 2018
Board Change

Midatech (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in... read more >

May 25, 2018
Midatech commences US clinical study of its investigational treatment for fatal childhood brain cancer

Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising... read more >

May 21, 2018
Midatech commences dosing in equivalence study

Midatech commences equivalence study in exploratory phase of Q-Octreotide (MTD201) for carcinoid... read more >

Mar 15, 2018
Midatech announces changes in Senior Management Team

Midatech (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising... read more >

Jan 9, 2018
Midatech receives confirmation that its Q-Octreotide (MTD201) first in-human EU study is approved

Midatech (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising... read more >

Jan 2, 2018
Midatech enters into a Loan Agreement with MidCap Financial

Midatech (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising... read more >

Dec 20, 2017
Midatech Pharma US initiates Gelclair® Phase IV trial to study oral mucositis in stem cell transplant patients

Trial to be conducted at the Dana-Farber / Brigham and Women’s Cancer Center to determine ability... read more >

Sep 6, 2017
Midatech to present at 19th Annual Rodman & Renshaw Global Investment Conference

Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and... read more >

Sep 4, 2017
Midatech submits MTD201 CTA filing for first in human study in carcinoid cancer and acromegaly

Midatech on track to start clinical development with MTD201 in Q4 2017

Midatech Pharma (AIM: MTPH,... read more >

Jul 26, 2017
Completion of pre-clinical liver cancer programme

Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and... read more >

Jul 18, 2017
Trading Update and Notice of Results

Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and... read more >

Jun 13, 2017
R&D manufacturing site visit for investors and analysts

Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products... read more >

Jun 9, 2017
Midatech signs global license agreement to investigate panobinostat for treatment of brain cancers

Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products... read more >

May 22, 2017
Midatech announces progress update on brain cancer therapies

Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products... read more >

Apr 11, 2017
Notice of Annual General Meeting 2017
Apr 4, 2017
Audited financial results for the year ended 31 December 2016

Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products... read more >

Mar 10, 2017
Midatech Announces Successful Initial Scale-Up of Its Sustained Release Manufacturing Facility

~ Q-Octreotide will become Midatech’s first Sustained Release product candidate manufactured in house at its state-of-the-art... read more >

Jan 20, 2017
Trading Update

Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and... read more >

© Copyright 2018 Midatech Pharma PLC